28 completed, 11 terminated, 2 recruiting, 2 unknown. 22 Phase 2, 18 Phase 1, 7 Phase 3, 2 Not applicable.
Follow Fenretinide: new trials by email Literature Review of Fenretinide trials Research Report on Fenretinide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer Fenretinide - Small Cell Lung Cancer | Phase 1 | Recruiting | SciTech Development, Inc. | 44 | 2025-12-11 | 2026-08-19 |
| Study to Examine the Effects of Oral Fenretinide ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue | Phase 2 | Completed | Island Pharmaceuticals | 15 | 2024-09-05 | 2025-10-24 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers Fenretinide, Placebo - Safety and Tolerability | Phase 1 | Completed | Island Pharmaceuticals | 25 | 2023-11-22 | 2025-01-27 |
| Study of LAU-7b for the Treatment of Long COVID in Adults LAU-7b for 3 cycles, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles - Long COVID | Phase 2 / Phase 3 | Completed | Laurent Pharmaceuticals Inc. | 272 | 2023-11-15 | 2026-01-06 |
| Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults LAU-7b, Placebo oral capsule - COVID-19 Disease | Phase 2 / Phase 3 | Terminated | Laurent Pharmaceuticals Inc. | 351 | 2020-08-18 | 2025-11-13 |
| Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults LAU-7b, Placebo oral capsule - Cystic Fibrosis | Phase 2 | Completed | Laurent Pharmaceuticals Inc. | 166 | 2018-11-05 | 2024-10-09 |
| Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Fenretinide - Peripheral T-cell Lymphoma | Phase 2 | Unknown | CerRx, Inc. | 140 | 2016-12-01 | 2019-07-23 |
| Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies Fenretinide (4-HPR) plus Intravenous Safingol - Solid Tumor | Phase 1 | Terminated | South Plains Oncology Consortium | 16 | 2016-11-01 | 2022-03-31 |
| Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine - Recurrent Neuroblastoma, Neuroblastoma | Phase 1 | Terminated | South Plains Oncology Consortium | 4 | 2014-05-01 | 2022-03-31 |
| Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis Fenretinide, Placebo - Cystic Fibrosis | Phase 1 | Completed | Elias Matouk | 15 | 2014-04-01 | 2016-07-12 |
| Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Fenretinide/LXS + Ketoconazole - Ovarian Cancer, Cancer of Ovary | Phase 1 / Phase 2 | Terminated | South Plains Oncology Consortium | 12 | 2012-02-01 | 2020-08-27 |
| Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Fenretinide, Cytarabine, Methotrexate - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | South Plains Oncology Consortium | 3 | 2010-08-01 | 2022-03-31 |
| Fenretinide in Healthy Young Women at Genetic and Familial Risk Fenretinide, Placebo - High-Risk Cancer | Phase 3 | Terminated | European Institute of Oncology | 20 | 2009-12-01 | 2018-11-07 |
| A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity Fenretinide, Placebo - Obesity, Insulin Resistance | Phase 2 | Suspended | University of California, San Diego | 21 | 2007-12-01 | 2021-02-10 |
| Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration Fenretinide - Geographic Atrophy, Dry Age Related Macular Degeneration | Phase 2 | Completed | Sirion Therapeutics, Inc. | 245 | 2006-12-01 | 2010-06-22 |
| N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma fenretinide, high performance liquid chromatography, pharmacological study - Neuroblastoma | Phase 1 | Completed | New Approaches to Neuroblastoma Therapy Consortium | 17 | 2006-12-01 | 2026-04-14 |
| Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors fenretinide, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | California Cancer Consortium | 21 | 2006-11-01 | 2013-09-12 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer fenretinide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | California Cancer Consortium | 29 | 2005-02-01 | 2017-07-19 |
Showing 20 of 46. Sign in to see all of them.
Neuroblastoma (5) · Head and Neck Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (3) · Lymphoma (3) · Ovarian Neoplasms (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Brain Neoplasms (2) · Burkitt Lymphoma (2) · Cystic Fibrosis (2) · Hodgkin Disease (2) · Inflammation (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · South Plains Oncology Consortium (5) · Laurent Pharmaceuticals Inc. (3) · Barbara Ann Karmanos Cancer Institute (2) · California Cancer Consortium (2) · Eastern Cooperative Oncology Group (2) · Island Pharmaceuticals (2) · SciTech Development, Inc. (2) · Beersheva Mental Health Center (1) · Cancer Therapeutics Research Group (1) · Case Comprehensive Cancer Center (1) · CerRx, Inc. (1) · Elias Matouk (1) · European Institute of Oncology (1)
United States (39) · Canada (5) · Australia (4) · Hong Kong (1) · Israel (1) · Italy (1) · Singapore (1)
Ali Moiin, MD (2) · Barry J Maurer, MD, PhD (2) · Jacek Pinski, MD (2) · Jean-Marie Houle, PhD (2) · Aaron R Mangold, M.D. (1) · Agustin Garcia (1) · Ajay Gopal (1) · Anita L. Sabichi, MD (1) · Ann F Mohrbacher, MD (1) · Ann Mohrbacher, MD (1) · Anna R Franklin, MD (1) · Auris O Huen, MD, PharmD (1) · Barbara Pro, MD (1) · Barry J. Maurer, MD, PhD (1) · Bert Slade, MD (1)
PMID 15514370, PMID 15744595, PMID 16849757, PMID 18172274, PMID 20082080, PMID 20878269, PMID 28420721, PMID 30836314, PMID 33331670, PMID 37199745
P30CA016672 (4), P30CA022453 (2), U01CA062487 (2), 2009 (1), N01CM17101 (1), N01CM62209 (1), P01CA081403 (1), P30CA033572 (1), P30CA043703 (1), R21CA097767 (1), R21CA119519 (1), U01CA062502 (1), U01CA062505 (1), U01CA070172 (1), U10CA037429 (1)